U.S. Markets closed

Blog Exposure - ADMA Biologics Received US Patent for Treating Respiratory Infections

Stock Monitor: Eleven Biotherapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMA as the Company's latest news hit the wire. On May 16, 2018, the New Jersey-based biopharmaceutical Company announced that the United States Patent and Trademark Office has issued to ADMA US Patent No. 9,969,793 covering methods of treating respiratory infections. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), which also belongs to the Healthcare sector as the Company ADMA Biologics. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ADMA Biologics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Detail of Patient Issued

The newly issued patent encompasses methods of treating upper and lower respiratory infections, including those caused by Respiratory Syncytial Virus (RSV), other viruses, as well as bacteria utilizing ADMA's investigational drug RI-002 that contains elevated, neutralizing antibody titers to RSV as well as elevated antibody titers to other respiratory pathogens, such as influenza virus, coronavirus, parainfluenza virus, and metapneumovirus. The term of the issued patent extends to January 2035.

The Patent is First of its Kind for Use of Polyclonal Immunoglobulin Preparation for Respiratory Infection Treatment

Adam Grossman, President and Chief Executive Officer of ADMA, stated that this patent is the first of its kind for use of a polyclonal immunoglobulin preparation for treatment of respiratory infection and, in conjunction with three previously issued patents to ADMA, further protects the Company's proprietary immune globulin technology for the prevention and treatment of infection.

According to Grossman, ADMA will continue to pursue additional US and international patents.

Grossman further added that ADMA remains committed to providing new avenues for treating patients at risk for or suffering from infection, including respiratory infections, while concurrently meeting or exceeding the high regulatory standards set by the United States Food and Drug Administration for immune globulin products. According to him, while the patent encompasses the therapeutic treatment of respiratory infection in any type of patient, the immune compromised and immunodeficient patient populations remain a top priority for ADMA and the medical community at large.

US Patents Issued in 2017

On November 15, 2017, the United States Patent and Trademark Office issued to the Company US Patent No. 9,815,886, relating to compositions and methods for the treatment of immunodeficiency. The patent encompassed immune globulin compositions (including ADMA's investigational drug RI-002 for the treatment of Primary Immune Deficiency Disease (PIDD)) containing elevated, neutralizing antibody titers to RSV as well as elevated antibody titers to other respiratory pathogens, such as influenza virus, coronavirus, parainfluenza virus, and metapneumovirus. The term of the issued patent extended to January 2035.

On July 31, 2017, ADMA was issued US Patent No. 9,714,283, which encompassed methods of providing immunotherapy to patients using immune globulin compositions proprietary to ADMA. The term of this patent extended to January 2035. The covered methods encompassed therapeutic and prophylactic treatments for a broad spectrum of immune compromised and immunodeficient patients via administration of RI-002.

About RI-002

RI-002, ADMA's lead product candidate, is a specialty plasma-derived, polyclonal, intravenous immune globulin (IGIV) derived from human plasma containing naturally occurring polyclonal antibodies as well as plasma from donors tested to have high levels of neutralizing antibodies to RSV. ADMA is pursuing an indication for the use of this specialty IGIV product for treatment of patients diagnosed with PIDD. Polyclonal antibodies are the primary active component of IGIV products. Data review indicates that the polyclonal antibodies present in RI-002 support its ability to prevent infections in immune-compromised patients.

About ADMA Biologics, Inc.

Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA is a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of PIDD and certain infectious diseases.

Stock Performance Snapshot

May 17, 2018 - At Thursday's closing bell, ADMA Biologics' stock rose 5.65%, ending the trading session at $5.42.

Volume traded for the day: 466.54 thousand shares, which was above the 3-month average volume of 119.27 thousand shares.

Stock performance in the last month – up 14.83%; previous three-month period – up 37.56%; past twelve-month period – up 39.69%; and year-to-date - up 68.85%

After yesterday's close, ADMA Biologics' market cap was at $235.82 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors